WHO ICTRP trial
Patient experience of transitioning between two brands of adalimumab (Humira and…
ISRCTN11094929 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN11094929 |
|---|---|
| Public title | Patient experience of transitioning between two brands of adalimumab (Humira and a biosimilar – Imraldi) in the treatment of adults with Crohn’s disease |
| Scientific title | IBD Reference and Biosimilar adalimumab CroSS over Study |
| Primary sponsor | University Hospital Southampton NHS Foundation Trust |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase IV |
| Countries | United Kingdom |
| Conditions | Crohn’s disease Digestive System Crohn disease [regional enteritis] |
| Interventions | This is a single-centre, prospective, randomised, single-blind, cross-over study in subjects with Crohn’s Disease (CD). As far as possible the study will mimic what would happen during a real-world cross over between reference product… |
| Registration date | Jul 24, 2019 |
| Target size | 150 |
| Secondary IDs | 2018-004967-30;Nil known;CPMS: 40987 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: